tamoxifen citrate
FDA Approved
Description
Tamoxifen is a selective estrogen receptor modulator (SERM) primarily used in breast cancer treatment. It has demonstrated efficacy in treating aggressive fibromatosis (desmoid tumors) and superficial fibromatosis by inhibiting fibroblast proliferation. Off-label use includes various fibroproliferative disorders.
Indications & Therapeutic Use
aggressive fibromatosis, desmoid tumors, superficial fibromatosis, Dupuytren contracture
Linked Diseases:
Global Availability (10 countries)
| Country | Access Route | Regulatory Pathway | Lead Time | Status |
|---|---|---|---|---|
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — |
Available Through
This drug is available for procurement through the following fulfilment partner.
Fulfilment Partner
tamoxifen citrate
| Generic Name | tamoxifen citrate |
| Brands | 1 brand available |
| Active Ingredient | tamoxifen citrate |
| Drug Class | aggressive fibromatosis |
| Manufacturer | AstraZeneca |
| Dosage Forms | Oral tablets 10mg, 20mg |
| Medical Code | L02BA01 |
| Orphan Status | No |
| Cold Chain | Not Required |
| Lead Time | 5 days |
| Reg. Status | FDA Approved |
| Clinical Trial | NCT00001704 |
| Countries | 10 countries |
Authority Signals
Last Verified3/21/2026
Data ConfidenceHigh (AI + Pharmacist)
Source Citations11 Validated Nodes